Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) Assets Average (2016 - 2025)

Historic Assets Average for Gyre Therapeutics (GYRE) over the last 17 years, with Q3 2025 value amounting to $156.0 million.

  • Gyre Therapeutics' Assets Average rose 2675.44% to $156.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $156.0 million, marking a year-over-year increase of 2675.44%. This contributed to the annual value of $121.0 million for FY2024, which is 2019.6% up from last year.
  • According to the latest figures from Q3 2025, Gyre Therapeutics' Assets Average is $156.0 million, which was up 2675.44% from $141.2 million recorded in Q2 2025.
  • Gyre Therapeutics' Assets Average's 5-year high stood at $156.0 million during Q3 2025, with a 5-year trough of $11.2 million in Q3 2023.
  • Its 5-year average for Assets Average is $87.1 million, with a median of $90.2 million in 2021.
  • As far as peak fluctuations go, Gyre Therapeutics' Assets Average plummeted by 8045.49% in 2023, and later surged by 100103.32% in 2024.
  • Over the past 5 years, Gyre Therapeutics' Assets Average (Quarter) stood at $67.1 million in 2021, then fell by 13.73% to $57.9 million in 2022, then rose by 9.27% to $63.3 million in 2023, then soared by 98.13% to $125.3 million in 2024, then grew by 24.49% to $156.0 million in 2025.
  • Its last three reported values are $156.0 million in Q3 2025, $141.2 million for Q2 2025, and $127.6 million during Q1 2025.